Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
hemorrhagic disease of newborn - Clinical Profile, Genes & Research | Kisho | Kisho
Rare Disease
hemorrhagic disease of newborn
MONDO:0006784
Also known as:vitamin K deficiency bleeding in newborn
Overview
A condition characterized as a coagulation disturbance in newborns due to vitamin K deficiency resulting in impaired production of coagulation factors II, VII, IX, and X, and proteins C and S by the liver.
ResearchLimited published research (5 articles)
Research Landscape
Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.
No clinical trials have been registered for hemorrhagic disease of newborn.
5 publications have been identified in PubMed for hemorrhagic disease of newborn. Research spans Review / Meta-Analysis (40%), Case Report / Case Series (40%), and Epidemiology / Natural History (20%).
Recent Publications
Zibara V (2026). [PMID: 41874099](https://pubmed.ncbi.nlm.nih.gov/41874099/). *Hematol Rep*. [Review / Meta-Analysis]
Lammers S (2025). [PMID: 40048733](https://pubmed.ncbi.nlm.nih.gov/40048733/). *Obstetrics and gynecology*. [Case Report / Case Series]
Clarke P (2024). [PMID: 38429074](https://pubmed.ncbi.nlm.nih.gov/38429074/). *Archives of disease in childhood. Fetal and neonatal edition*. [Review / Meta-Analysis]
Elsebey M (2024). [PMID: 38681352](https://pubmed.ncbi.nlm.nih.gov/38681352/). *Cureus*. [Case Report / Case Series]
Evim MS (2024). [PMID: 39687930](https://pubmed.ncbi.nlm.nih.gov/39687930/). *Research and practice in thrombosis and haemostasis*. [Epidemiology / Natural History]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 6:25 PM UTC
Diseases are connected by shared genes, phenotypes, therapeutic targets, and MONDO disease hierarchy. The Rare badge reflects Kisho's rarity classification — scored from authoritative sources including OMIM, Orphanet, orphan drug designations, clinical trial activity, and published prevalence data.
Generic drugmakers will face import tariffs in the U.S., President Donald Trump announced this week. Samsung Biologics is pursuing the biggest M&A deal ever for a Korean biopharma company. | Generic drugmakers will face import tariffs in the U.S., President Donald Trump announced this week. 3. ‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong · In a first for a U.S. biotech, Axiom Biosciences plans to go public on the Hong Kong Stock Exchange first, followed by a double listing on the Nasdaq. The company’s international investor pool, coupled with a partnership with Korea’s Medinno on its lead cell therapy for two fatal newborn neurological diseases, made the Hong Kong listing an easy choice, CEO Remo Moomiaie-Qajar, M.D., said. Generic drugmakers will face import tariffs in the U.S., President Donald Trump announced this week. Samsung Biologics is pursuing the biggest M&A deal ever for a Korean biopharma company. In an unconventional move, a U.S. biotech is gunning for an IPO in Hong Kong first. India has seen some “green shoots” of biotech innovation, with more than 10 novel assets by local drugmakers over the past decade, according to a new report from HealthKois and Boston Consulting Group. India’s annual pharma R&D spend, at around $2 billion to $3 billion, continues to lag that of other countries, but the Indian government is funding emerging technologies. Fierce Pharma Asia Donald Trump Samsung BioLogics biotech IPO M&A tariffs Hong Kong India Legend Biotech Johnson & Johnson Summit Therapeutics Takeda Roche Zhejiang Huahai gene therapy Asia Pharma
Generic drugmakers will face import tariffs in the U.S., President Donald Trump announced this week. Samsung Biologics is pursuing the biggest M&A deal ever for a Korean biopharma company. | Generic drugmakers will face import tariffs in the U.S., President Donald Trump announced this week. 3. ‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong · In a first for a U.S. biotech, Axiom Biosciences plans to go public on the Hong Kong Stock Exchange first, followed by a double listing on the Nasdaq. The company’s international investor pool, coupled with a partnership with Korea’s Medinno on its lead cell therapy for two fatal newborn neurological diseases, made the Hong Kong listing an easy choice, CEO Remo Moomiaie-Qajar, M.D., said. Generic drugmakers will face import tariffs in the U.S., President Donald Trump announced this week. Samsung Biologics is pursuing the biggest M&A deal ever for a Korean biopharma company. In an unconventional move, a U.S. biotech is gunning for an IPO in Hong Kong first. India has seen some “green shoots” of biotech innovation, with more than 10 novel assets by local drugmakers over the past decade, according to a new report from HealthKois and Boston Consulting Group. India’s annual pharma R&D spend, at around $2 billion to $3 billion, continues to lag that of other countries, but the Indian government is funding emerging technologies. Fierce Pharma Asia Donald Trump Samsung BioLogics biotech IPO M&A tariffs Hong Kong India Legend Biotech Johnson & Johnson Summit Therapeutics Takeda Roche Zhejiang Huahai gene therapy Asia Pharma
